

EFFECT OF RENAL TRANSPLANTATION ON ADRENOMEDULLIN LEVELS IN DIABETIC CHRONIC KIDNEY DISEASE PATIENTS

Thesis

Study Submitted for
Partial fulfillment of M.D. in Internal Medicine

By

Ahmed Afkar Hussein
(M.B.B.Ch.)

Supervised by

Prof. Dr. Mohammed Hany Hafez

Professor of Internal Medicine and Nephrology
Faculty of Medicine, Cairo University

Prof. Dr. Ashraf Sabry Genaina


Assistant Professor of Internal Medicine and Nephrology
Faculty of Medicine, Beni-Suef University

Prof. Dr. Nehad Ahmed Mossad

Assistant Professor of Clinical Pathology
Faculty of Medicine, Cairo University

**Faculty of Medicine
Cairo University**

2014



Acknowledgment

*My unlimited gratitude respect and thanks are due to **Professor Dr. Mohammed Hany Hafez**, Professor of Internal Medicine and Nephrology, Faculty of Medicine, Cairo University for his generosity in time and guidance.*

*I owe **Assistant Professor Dr. Ashraf Genaina**, Assistant Professor of Internal Medicine Faculty of Medicine, Beni Suef University, the most for his encouragement unyielding support and contribution in time and effort in this work,*

*I am greatly indebted to **Assistant Professor Dr. Nehad Mossad**, Assistant professor of Clinical Pathology Faculty of Medicine, Cairo University, for her efforts in making this work. I would like to thank her for her continuous guidance and in valuable supervision.*

Last but not least I would like to thank my wife and my parents who helped me a lot. I would like to thank all the patients who contributed in this study and wish them a speedy and complete recovery.

Abstract

Other studies will be useful to determine whether adrenomedullin infusion might improve renal dysfunction, as it has been shown to be beneficial after myocardial infarction. Further studies are needed to compare mAM and other humoral factors as predictive factors of mortality and morbidity in transplant patients. Further studies are necessary to clarify the pathophysiologic role of mAM in transplant patients complicated with various cardiovascular diseases (peripheral artery disease, stroke, heart failure, etc.) especially the diabetics who are most liable for these complications.

Keyword

ALT- HbA1C- LPS- TNF- α

LIST OF CONTENTS

Title	Page
List of Abbreviations	i
List of Tables	iii
List of Figures	v
Introduction	1
Aim of The Work	3
Review of Literature	
Biomarkers In Renal Transplantation	4
Adrenomedullin	14
Adrenomedullin In Diabetes And Renal Transplantation ...	42
Subjects And Methods	52
Results	63
Discussion	91
Conclusion	104
Summary	105
References	107
Arabic Summary	—

LIST OF ABBREVIATIONS

iAMD	: Adrenomedullin-2, intermedin
ACEI	: Angiotensin-converting enzyme inhibitors
ADM	: Adrenomedullin
AII	: Angiotensin II
ALT	: Alanine transaminase
AMBP	: Adrenomedullin binding protein
ANP	: Atrial natriuretic peptide
AP-2	: Activator Protein-2
AR	: Acute Rejection
AST	: Aspartate transaminase
BMI	: Body Mass Index
BNP	: Brain natriuretic peptide
CD	: Cluster of Differentiation
CGRP	: Calcitonin gene-related peptide
CHF	: Congestive heart failure
CRLR	: Calcitonin Receptor Like Receptor
DGF	: Delayed Graft Function
DM	: Diabetes Mellitus
EDTA	: Ethylene Diamine TetraAcetate
EGF	: Epidermal Growth Factor
EF	: Ejection fraction
ELISA	: Enzyme Linked Immunosorbant Assay
ESRD	: End Stage Renal Disease
ET-1	: Endothelin-1
FS	: Fractional shorting
Hb	: Hemoglobin
HbA1C	: Glycoslated HB
HF	: Heart failure
HLA	: Human Leucocyte Antigen
HR	: Heart rate
IF/TA	: Interstitial Fibrosis/Tubular Atrophy

LIST OF ABBREVIATIONS (CONT...)

LPS	: Lipopolysaccharide
LVEDD	: Left ventricular end diastolic dimensions
LVESD	: Left ventricular end systolic dimensions
MAP	: Mean Arterial Pressure
MICA	: MHC- class1 related A chain
NEP	: Neutral endopeptidase
NIH	: National Institute of Health
NO	: Nitric oxide
NYHA	: New York Heart Association
PAMP	: Pro-adrenomedullin N-terminal 20 peptide
PAP	: Pulmonary artery pressure
PKC	: Protein Kinase C
ROC	: Receiver Operating Characteristic curves
RTx	: Renal Transplantation
TGF	: Transforming Growth Factor
TNF-α	: Tumor necrosis factor
VIP	: Vasoactive Intestinal Peptide
VSMC	: Vascular smooth muscle cell

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Multiple functions of adrenomedullin.....	23
Table (2):	Renal Actions of AM which help to control blood pressure:	26
Table (3):	AM Anti-inflammatory effect: immune sources, receptors and effects	27
Table (4):	Disease states associated with elevated plasma adrenomedullin	34
Table (5):	Natural history of diabetic nephrology:.....	44
Table (6):	Demographic and anthropometric data of study population.....	64
Table (7):	Age distribution of study population.....	65
Table (8):	Clinical characteristics of study patients	66
Table (9):	Anti-hypertensives used by patient groups.....	67
Table (10):	MAP of study population.....	68
Table (11):	Urea levels in study population.....	70
Table (12):	Creatinine levels in study population	72
Table (13):	Sodium levels	73
Table (14):	Total bilirubin levels.....	74
Table (15):	Liver enzyme levels.....	75
Table (16):	ALT levels.....	76
Table (17):	Calcium levels	77
Table (18):	Albumin levels	78
Table (19):	Haemoglobin levels	79
Table (20):	Platelet levels.....	80
Table (21):	Random blood sugar levels.....	81
Table (22):	HbA1c levels pre-transplantation.....	82

List of Tables (Cont...)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (23):	LVD parameter by echocardiography	83
Table (24):	EF parameter by echocardiography.....	84
Table (25):	Adrenomedullin levels in study population.....	85
Table (26):	Adrenomedullin correlation in non-diabetics pre- and postTx.....	87
Table (27):	Adrenomedullin correlation pre-Tx in diabetics and non-diabetics	87
Table (28):	ADM correlation post-TX in diabetics and non- diabetics	88
Table (28):	Correlation between mAM and other demographic, clinical, and biochemical parameters	89

List of Figures (Cont...)

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Possible pathways for biomarker discovery in kidney transplantation	9
Figure (2):	The peptide sequence of AM showing the disulfide bond forming a 6-peptide ring.....	15
Figure (3):	The gene encoding for AM situated on chromosome 11 contains 4 exons and 3 introns.....	17
Figure (4):	The consensus sequences for binding sites of transcription factors at the promoter region of the human AM gene.....	17
Figure (5):	Putative regulatory mechanism of adrenomedullin (AM) gene expression.	20
Figure (6):	The CGRP/adrenomedullin (AM) receptor model	22
Figure (7):	Plasma levels of adrenomedullin in patients with essential hypertension, chronic renal failure and heart failure.	35
Figure (8):	Interplay of factors in diabetic nephropathy	45
Figure (9):	The principle of an assay system for human m-AM ...	60
Figure (10):	Sex distribution in study.....	64
Figure (11):	Age distribution.....	65
Figure (12):	MAP of study population	68
Figure (13):	Urea levels in study population	70
Figure (14):	Creatinine levels in study population.....	72
Figure (15):	Sodium levels in study population.....	73
Figure (16):	Total bilirubin levels	74
Figure (17):	AST levels.....	75
Figure (18):	ALT levels	76
Figure (19):	Calcium levels.....	77
Figure (20):	Albumin levels	78

List of Figures (Cont...)

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (21):	Haemoglobin levels.....	79
Figure (22):	Platelet levels	80
Figure (23):	Random blood sugar levels	81
Figure (24):	HbA1c levels pre-transplantation	82
Figure (25):	LVD parameter by echocardiography.....	83
Figure (26):	LVD parameter by echocardiography.....	84
Figure (27):	Adrenomedullin levels in study population	85
Figure (28):	Adrenomedullin correlation in diabetics pre-and postTx	86
Figure (29):	Adrenomedullin correlation pre-Tx in diabetics and non-diabetics	87
Figure (30):	ADM correlation post-TX in diabetics and non- diabetics	88
Figure (31):	Adrenomedullin correlation with random blood sugar.....	90
Figure (32):	Adrenomedullin correlation with creatinine	90

INTRODUCTION

Since the 1950s, kidney disease has been clearly recognized as a common complication of diabetes mellitus (DM), with as many as 50% of patients with DM of more than 20 years duration having this complication. The risk for the development of diabetic nephropathy is low in a normo-albuminuric patient with diabetes' duration of greater than 30 years. Patients who have no proteinuria after 20-25 years have a risk of developing overt renal disease of only approximately 1% per year (*Pavkov et al., 2006*). Diabetes itself, remains one of the most common causes of ESRD.

As for any other patient with ESRD, diabetic patients with ESRD can be offered renal replacement therapy usually in the form of haemodialysis. In patients with diabetic nephropathy, starting at a creatinine clearance or estimated GFR of 15 mL/min is wise. Starting earlier may be useful when hypervolemia renders blood pressure uncontrollable, when the patient experiences anorexia and cachexia or other uremic symptoms, and when severe vomiting is the combined result of uremia and gastroparesis. Amongst the options of RRT is renal transplantation (eg, cadaver donor kidney, living related-donor kidney, living unrelated-donor kidney [emotionally related donor], living unrelated-donor kidney [unrelated by family or emotionally; the so-called altruistic donor], pancreas plus kidney transplantation (*Shlipak, 2009*). Transplantation offers an excellent option for restoring a healthy productive life besides reducing the overall medical care costs on the long-run. This has attracted researchers to focus on all possible means to improve the outcome of such procedure and limit any possible complications which would certainly benefit both the patient and his society. This opened the door for biomarkers.

A new era has emerged in the medical field with the use of biomarkers as diagnostic and therapeutic agents of various medical diseases. Due to limitations of currently used kidney function markers (*Iliadis et al., 2011*), there has been extensive study of biomarkers as traceable substances which are objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention (*Deverajan, 2007*).

Of these, adrenomedullin is a newly emerging biomarker expected to have a role in the patho-physiology of renal haemodynamics in the native kidney and non-the-less the transplanted kidney too. It is suggested that adrenomedullin may play an important role in the regulation of systemic vascular tone, control of cardiorenal homeostasis and may influence the cardiovascular dysfunction (*Yamagushi et al., 1996*).

In the following pages of this study, we made an effort to highlight the effect of renal transplantation on the levels of adrenomedullin in diabetic renal patients and the possibility of using it as a biomarker in the detection of early rejection.



AIM OF THE WORK

- 1- To assess the effect of renal transplantation on adrenomedullin levels in the first postoperative week.
- 2- To highlight the potential effect of diabetes on adrenomedullin levels.
- 3- Raise the hypothetic role of adrenomedullin in the pathophysiology of diabetes and renal failure.

Biomarkers in Renal Transplantation

In kidney transplantation, significant improvements in short-term allograft survival have been accomplished

However, despite improvement over the years in immunosuppressant strategies, late kidney allograft loss remains the main clinical challenge for long-term graft survival with close to 5000 kidney transplants failing each year in the USA alone. Kidney transplant failure is now a leading cause of end-stage renal disease (*Hariharan et al., 2000*).

Thus, there is a critical need for new effective biomarkers for accurate monitoring of graft function, early diagnosis of rejection, treatment response, and surrogate end point and outcome prediction in organ transplantation, leading to a tailored and individualized treatment (*Meier-Kriesche et al., 2004*) to improve outcomes in a noninvasive, cost-effective manner.

Recently, a NIH working group recommended preferred terms and definitions that have broad applications (*Biomarkers Definition Working Group, 2001*).

- Biological marker (biomarker): a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.
- Clinical end point: a characteristic or variable that reflects how a patient feels or functions, or how long a patient survives.
- Surrogate end point: a biomarker intended to substitute a clinical end point. A clinical investigator uses epidemiologic,

therapeutic, pathophysiologic or other scientific evidence to select a surrogate end point that is expected to predict clinical benefit, harm or lack of benefit or harm.

The introduction of molecular medicine has resulted in an amazing increase in the discovery of new biomarkers. Much of this is related to the advances in new technologies such as genomics, proteomics and imaging. Furthermore, the expansions in technologies and innovative applications towards translational medicine have driven biomarkers into the focus of drug discovery and development in recent years. However, there is still no routine application of any of these markers in clinical transplantation.

The Human Genome Project and Genomic Sciences resulted in valuable insights into the mechanisms of the genome and have produced a large quantity of tools (*Cunningham, 2000*). These tools are enabling a detailed analysis of the expression of the complete set of genes encoded in the genome and are collectively referred to as the ‘omics’ technologies. The knowledge base being developed by the genomics revolution, through its associated technologies, is impacting on the practice of all of the biological sciences.

Major obstacles in the management of transplant recipients include:

- Most accessible methods for evaluating kidney function are either ineffective, inaccurate or highly invasive, such as tissue biopsies.
- Lack of reliable markers useful for immune monitoring or predicting long-term graft function. in the clinical routine. This is partly due to the lack of well-defined end points and short follow-up times in validation studies. Furthermore, it reflects the absence of robust metrics and a reliance on ‘subjective’ measures.